---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-113159"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:08:03.434266+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025

## Summary
- Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.
- FDA approved LYMPHIR for relapsed/refractory CTCL; commercial launch planned H1 2025.
- Pre-commercial activities: J-code application, NCCN inclusion, CSO recruitment, inventory built.
- R&D $4.9M, G&A $8.1M, stock-based comp $7.5M vs $4.2M, $5.9M, $2.0M YoY.
- Phase I combo with pembrolizumab showed 27% ORR, 33% CBR, median PFS 57 weeks in gynecological tumors.

## SEC filing metadata
- accession: 0001213900-24-113159
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/0001213900-24-113159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/ea0226165-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-113159
- JSON: https://secwatch.observer/filing/0001213900-24-113159.json
- Plain text: https://secwatch.observer/filing/0001213900-24-113159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.